Allarity Therapeutics (ALLR) Restructuring Costs (2021 - 2022)
Allarity Therapeutics' (ALLR) quarterly Restructuring Costs came in at $268000.0 in Q3 2022, down 29.66% YoY from $381000.0 in Q3 2021, and up 587.18% on a QoQ basis from $39000.0 in Q2 2022.
Allarity Therapeutics (ALLR) Restructuring Costs (2021 - 2022) Analysis & Trends
Allarity Therapeutics (ALLR) has 2 years of Restructuring Costs data on file, last reported at $268000.0 in Q3 2022.
- Quarterly Restructuring Costs fell 29.66% year-over-year to $268000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $344000.0 (changed N/A YoY) and the FY2021 annual result came in at $129000.0, changed N/A from the prior year.
- Restructuring Costs improved to $268000.0 in Q3 2022, from $39000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $703000.0 in Q1 2022 to a low of -$666000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Allarity Therapeutics | 23.23 Mn | 23.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 268,000.00 |
| Jun 30, 2022 | 39,000.00 |
| Mar 31, 2022 | 703,000.00 |
| Dec 31, 2021 | -666,000.00 |
| Sep 30, 2021 | 381,000.00 |
| Jun 30, 2021 | 285,000.00 |